登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验,由贵州医科大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07936578,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Previously untreated, histopathologically or cytologically confirmed unresectable PD-L1 TPS ≥ 1% Stage IV non-small cell lung cancer
入选标准第 3 条
Childbearing age women must have a serum pregnancy test within 3 days before the first dose, and the result must be negative. Female subjects of childbearing age and male subjects with partners of childbearing age must agree to use highly effective methods of contraception during the study and for 180 days after the last dose of the study drug.
入选标准第 11 条
Patients with a history of another malignancy within 5 years before the first dose, other than non-small cell lung cancer, are excluded. This exclusion does not apply to malignancies with a negligible risk of metastasis or death (e.g., expected disease-free survival >5 years) that are expected to achieve a curative outcome after treatment (e.g., adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, or ductal carcinoma in situ treated with curative-intent surgery).
排除标准第 11 条
ECOG performance status score of 0-1
入选标准第 7 条
Have measurable lesions according to Response Evaluation Criteria in Solid Tumors version 1.1
入选标准第 4 条
Known human immunodeficiency virus (HIV) infection (known HIV antibody positive)
排除标准第 7 条
Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study.
排除标准第 14 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07936578,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Have fully understood this study and voluntarily signed the Informed Consent Form (ICF) Aged 18 to 75 years, regardless of gender Previously untreated, histopathologically or cytologically confirmed unresectable PD-L1 TPS ≥ 1% Stage IV non-small cell lung cancer Have measurable lesions according to Response Evaluation Criteria in Solid Tumors version 1.1 Have adequate pulmonary function tests (PFTs) Subjects must be able to provide a prior driver gene report based on tissue or blood testing, and the test results must show that targetable driver genes such as EGFR sensitive mutations, ALK rearrangement or fusion, and ROS1 fusion are all negative; or if a certain type of driver gene is positive but the targeted drug is not available, the subject may be enrolled. If the subject does not have a driver gene test report, tumor samples (archived or fresh, primary or metastatic) or blood samples must be collected before enrollment for driver gene testing to confirm negativity (at a local laboratory or central laboratory) ECOG performance status score of 0-1 Adequate organ and bone marrow function Endocrine System: Thyroid-stimulating hormone (TSH) within normal limits. Note: If TSH is not within the normal range at baseline, the subject may still meet the inclusion criteria if T3 and free T4 are within the normal range;Coagulation function: International Normalized Ratio (INR) or Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN, except for subjects receiving anticoagulant therapy, as long as PT or aPTT is within the intended therapeutic range of the anticoagulant drug. Willing and able to comply with the study plan's visits, treatment plans, laboratory tests, and other study procedures. Childbearing age women must have a serum pregnancy test within 3 days before the first dose, and the result must be negative. Female subjects of childbearing age and male subjects with partners of childbearing age must agree to use highly effective methods of contraception during the study and for 180 days after the last dose of the study drug.排除标准:Exclusion Criteria:
Presence of resectable or metastatic disease History of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring steroid therapy, or currently receiving drug treatment or other clinical interventions, or presence of active pulmonary interstitial lesions or imaging findings of interstitial lung disease. Known history of active tuberculosis Known active infection requiring systemic therapy Any known or suspected autoimmune disease or immunodeficiency, except for: patients with a history of hypothyroidism who do not require hormone therapy or are receiving physiological doses of hormone replacement therapy; patients with stable blood glucose-controlled type 1 diabetes. Uncontrolled active hepatitis B (defined as positive hepatitis B surface antigen [HBsAg] test at screening with HBV-DNA levels above the upper limit of normal of the study center's laboratory; patients with HBV-DNA <500 IU/mL within 28 days before enrollment who have received at least 14 days of standard local antiviral therapy and are willing to continue antiviral therapy during the study may be enrolled); active hepatitis C (defined as positive hepatitis C virus surface antibody [HCsAb] test at screening with positive HCV-RNA). Known human immunodeficiency virus (HIV) infection (known HIV antibody positive) Vaccination with live vaccines within 30 days before the first dose, including but not limited to: mumps, rubella, measles, varicella/zoster (chickenpox), yellow fever, rabies, BCG, and typhoid vaccine (inactivated virus vaccines are allowed). History of severe allergic reactions to other monoclonal antibodies; Known severe or uncontrolled underlying diseases Patients with a history of another malignancy within 5 years before the first dose, other than non-small cell lung cancer, are excluded. This exclusion does not apply to malignancies with a negligible risk of metastasis or death (e.g., expected disease-free survival >5 years) that are expected to achieve a curative outcome after treatment (e.g., adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, or ductal carcinoma in situ treated with curative-intent surgery). Class III-IV congestive heart failure (New York Heart Association classification), poorly controlled and clinically significant arrhythmias. Any arterial thrombosis, embolism, or ischemia within 6 months before enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study. Investigators consider other conditions that may make the patient unsuitable for participation in this clinical trial.
引自 ClinicalTrials.gov, NCT07936578, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07936578,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。